Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.

Troy Querec | Soumaya Bennouna | Sefik Alkan | Yasmina Laouar | Keith Gorden | Richard Flavell | Shizuo Akira | Rafi Ahmed | Bali Pulendran
The Journal of experimental medicine | 2006

The live attenuated yellow fever vaccine 17D (YF-17D) is one of the most effective vaccines available, with a 65-yr history of use in >400 million people globally. Despite this efficacy, there is presently no information about the immunological mechanisms by which YF-17D acts. Here, we present data that suggest that YF-17D activates multiple Toll-like receptors (TLRs) on dendritic cells (DCs) to elicit a broad spectrum of innate and adaptive immune responses. Specifically, YF-17D activates multiple DC subsets via TLRs 2, 7, 8, and 9 to elicit the proinflammatory cytokines interleukin (IL)-12p40, IL-6, and interferon-alpha. Interestingly, the resulting adaptive immune responses are characterized by a mixed T helper cell (Th)1/Th2 cytokine profile and antigen-specific CD8+ T cells. Furthermore, distinct TLRs appear to differentially control the Th1/Th2 balance; thus, whilst MyD88-deficient mice show a profound impairment of Th1 cytokines, TLR2-deficient mice show greatly enhanced Th1 and Tc1 responses to YF-17D. Together, these data enhance our understanding of the molecular mechanism of action of YF-17D, and highlight the potential of vaccination strategies that use combinations of different TLR ligands to stimulate polyvalent immune responses.

Pubmed ID: 16461338

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: U19 AI057266
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK057665
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI056499
  • Agency: NIAID NIH HHS, United States
    Id: R21 AI056957
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI048638
  • Agency: NIAID NIH HHS, United States
    Id: U54 AI057157

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

SW480 (tool)

RRID:CVCL_0546

Cell line SW480 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

C3H/HeJ (tool)

RRID:IMSR_JAX:000659

Mus musculus with name C3H/HeJ from IMSR.

View all literature mentions

Abcam HeLa CCL2 KO (tool)

RRID:CVCL_B1MH

Cell line Abcam HeLa CCL2 KO is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HEK293 (tool)

RRID:CVCL_0045

Cell line HEK293 is a Transformed cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Vero (tool)

RRID:CVCL_0059

Cell line Vero is a Spontaneously immortalized cell line with a species of origin Chlorocebus sabaeus

View all literature mentions